Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids

Journal of Pediatrics

Volumn 156, Issue 2, 2010, Pages 302-307

  Levy, Deborah M ^a   Bingham, C April ^b   Kahn, Philip J ^c   Eichenfield, Andrew H ^a   Imundo, Lisa F ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPHENIDATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; THYROXINE;

ARTICLE; CALCINOSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; FEMALE; HUMAN; JOINT CONTRACTURE; LIPODYSTROPHY; MALE; MUSCLE ATROPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 74649086300     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.09.008     Document Type: Article

References (32)

1. Bowyer S.L., Blane C.E., Sullivan D.B., and Cassidy J.T. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103 (1983) 882-888
2. Reed A.M., and Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs 4 (2002) 315-321
3. Miller L.C., Sisson B.A., Tucker L.B., DeNardo B.A., and Schaller J.G. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 35 (1992) 1143-1149
4. Ramanan A.V., Campbell-Webster N., Ota S., Parker S., Tran D., Tyrrell P.N., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52 (2005) 3570-3578
5. Al-Mayouf S., Al-Mazyed A., and Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19 (2000) 138-141
6. Zeller V., Cohen P., Prieur A.M., and Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis: experience and longterm followup of 6 cases. J Rheumatol 23 (1996) 1424-1427
7. Reiff A., Rawlings D.J., Shaham B., Franke E., Richardson L., Szer I.S., et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 24 (1997) 2436-2443
8. Olson N.Y., and Lindsley C.B. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16 (1989) 1545-1547
9. Woo T.Y., Callen J.P., Voorhees J.J., Bickers D.R., Hanno R., and Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10 (1984) 592-600
10. Heckmatt J., Hasson N., Saunders C., Thompson N., Peters A.M., Cambridge G., et al. Cyclosporin in juvenile dermatomyositis. Lancet 1 (1989) 1063-1066
11. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 (1993) 1993-2000
12. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291 (2004) 2367-2375
13. Barbasso Helmers S., Dastmalchi M., Alexanderson H., Nennesmo I., Esbjörnsson M., Lindvall B., et al. Limited effects of high-dose intravenous immunoglobulin (IVIg) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 66 (2007) 1276-1283
14. Lang B.A., Laxer R.M., Murphy G., Silverman E.D., and Roifman C.M. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91 (1991) 169-172
15. Breems D.A., de Haas P.W., Visscher F., Sabbe L.J., Busch H.F., and van Doorn P.A. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis]. Ned Tijdschr Geneeskd 137 (1993) 1979-1982
16. Tsai M.J., Lai C.C., Lin S.C., Chiang B.L., Chou C.C., and Hsieh K.H. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 38 (1997) 111-115
17. Galeazzi M., Bellucci A.M., Girardelli C.R., Bono R., De Pita O., and Puddu P. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 15 (1996) 215-216
18. Kokori H., Fotoulaki M., Giannakopoulou C., Hatzidaki E., Tantros S., and Sbyrakis S. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int 41 (1999) 696-697
19. Roifman C.M. Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J Clin Immunol 15 (1995) 42S-51S
20. Sansome A., and Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child 72 (1995) 25-28
21. Al-Mayouf S.M., Laxer R.M., Schneider R., Silverman E.D., and Feldman B.M. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27 (2000) 2498-2503
22. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (1975) 344-347
23. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975) 403-407
24. Plamondon S., and Dent P.B. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 27 (2000) 2031-2034
25. Laxer R.M., Stein L.D., and Petty R.E. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 30 (1987) 328-334
26. Eisenstein D.M., Paller A.S., and Pachman L.M. Juvenile dermatomyositis presenting with rash alone. Pediatrics 100 (1997) 391-392
27. Pachman L.M., Abbott K., Sinacore J.M., Amoruso L., Dyer A., Lipton R., et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 148 (2006) 247-253
28. Huber A.M., Lang B., LeBlanc C.M., Birdi N., Bolaria R.N., Malleson P., et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 (2000) 541-549
29. Ramanan A.V., and Feldman B.M. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28 (2002) 833-857
30. Manlhiot C., Tyrrell P.N., Liang L., Atkinson A.R., Lau W., and Feldman B.M. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 121 (2008) e626-e630
31. Huber A.M., Feldman B.M., Rennebohm R.M., Hicks J.E., Lindsley C.B., Perez M.D., et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50 (2004) 1595-1603
32. Ruperto N., Ravelli A., Pistorio A., Ferriani V., Calvo I., Ganser G., et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (2008) 4-13